Advancing excellence in laboratory medicine for better healthcare worldwide
All news

Register to the IFCC Live Webinar on 28th October, 2021 "Alzheimer’s disease therapeutics & biofluid tests: current practice and future prospects"

Published: Thursday, October 21, 2021

28th October 2021
Don't miss the next IFCC webinar!

Dear Colleagues,

The next IFCC webinar on “Alzheimer’s disease therapeutics & biofluid tests: Current practice and future prospects” will be held on Oct 28, 2021.

This session will provide an overview of the rapidly evolving landscape of: (i) the use, reporting and interpretation of cerebrospinal fluid (CSF) Alzheimer’s disease biomarkers in clinical care, (ii) the development of peripheral (i.e.,blood-based) biomarkers and assays for Alzheimer’s disease, and (iii) the state of disease-modifying therapeutics for Alzheimer’s disease, including current and future uses of biomarkers related to therapeutics.

Routine imaging technologies (e.g., magnetic resonance imaging) and observation of clinical syndromes have demonstrated only modest accuracy for diagnosing Alzheimer’s disease in cognitively impaired individuals. As such, biomarkers are needed to help differentiate neurodegenerative disorders with overlapping phenotypes, particularly in the early stages of disease when diagnosis can be challenging and there is the greatest treatment potential.

On the basis of extensive evidence, a core set of CSF biomarkers for Alzheimer’s disease are now recommended by the international community for use in patient care, and the ever-expanding data on blood-based biomarkers suggests new roles in research and patient care. For CSF biomarkers, we will review the clinical use scenarios and implementation considerations for clinical laboratories. For blood-based biomarkers, we will review key biomarkers and associated analytical approaches, as laboratorians need to be aware the strengths and weaknesses of these emerging assays and proposed use scenarios.

We will also review advancements indisease-modifying therapies for Alzheimer’s disease and discuss current applications of CSF and blood-based biomarker testing in clinical trials, and anticipated future uses in guiding therapy decisions.

Chair: Dr. Robert Rissman (USA)

  • Talk 1: A primer on Alzheimer’s neuropathology and current treatments - Dr. Haakon B. Nygaard (Canada)
  • Talk 2: Clinical implementation of CSF biomarkers for Alzheimer’s disease - Dr. Mari DeMarco (Canada)
  • Talk 3: Blood-based biomarkers of Alzheimer’s disease - Dr. Melissa Budelier (USA)

A Certificate of participation will be provided at the end of this webinar. Please feel free to share this event in your social media with #IFCCLive Webinars

Register here:
https://www.workcast.com/register?cpak=5390610616631173 

Time Zones: Live presentations starting at 9:30 AM Pacific Time (Vancouver), 6:30 PM European Time (Rome), 1:30 PM Argentina Time (Buenos Aires) on Oct 28, 2021

Please ensure that you carefully determine the time that the presentation will start in your global time zone. To convert to your time zone click here

If you miss the live event, on demand webinar will be available after 24 /48 hours of the live event.

Certificate of Participation: available for all participants.

The IFCC Live Webinar Series is partially sponsored by Siemens and Boston Children's Hospital

 

    

 
Website developed by Insoft